The global beta-thalassemia (B-thal) market is estimated to be valued at US$ 411.8 million in 2021 and is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028).
The increasing incidence of beta-thalassemia is expected to drive the growth of the global beta-thalassemia (B-thal) market over the forecast period.
Rising number of patient population suffering from beta-thalassemia globally is anticipated to drive the market growth over the forecast period.
For instance, according to the report published by Bristol-Myers Squibb Company, a global biopharmaceutical company, in November 2018, stated that about 1.5% of the global population (an estimated 80-90 million people) are carriers of β-thalassemia. Although β-thalassemia is relatively rare in the U.S., there are an estimated 1.25 million carriers, making up 0.4% of the population. Moreover, according to the same source, thalassemia affects about 2,000 patients living in the U.S., with 1,000 patients having β-thalassemia major.
For instance, according to the article published in the Journal of European Hematology Association in June 2019, stated that the annual incidence of symptomatic individuals suffering from β-thalassemia is estimated at between one in 100,000 worldwide and one in 10,000 in Europe.
Figure 2. Global Beta-thalassemia (B-thal) Market Value (US$ Mn), By Treatment, 2021
The increasing research and development activities for the development and approval of novel therapeutics for the treatment of beta-thalassemia is expected to drive the market growth over the forecast period.
Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of beta-thalassemia, which is expected to drive growth of the global beta-thalassemia (B-thal) market over the forecast period.
For instance, in September 2021, Bluebird bio, a U.S. based biotechnology company, announced that its beti-cel gene therapy had been officially submitted for approval in the U.S., for the treatment of beta-thalassemia. Beti-cel was tested in multiple early- and late-stage clinical trials as a one-time treatment for beta-thalassemia, a rare condition that impairs the production of hemoglobin, the oxygen-carrying protein in red blood cells. Bluebird bio, a biopharmaceutical company is submitted the approval letter to the Food and Drug Administration to approve its therapy for adults and children with beta-thalassemia who need regular transfusions of red blood cells. Beti-cel is already cleared for market in Europe, where it's sold under the brand name Zynteglo.
Beta-thalassemia (B-thal) Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients